On November 10, Johnson & Johnson Medical Technology officially announced that it has signed a cooperation agreement with Jiangsu Changyida Medical Technology Co., Ltd. (hereinafter referred to as Changyida) to deepen cooperation on the next-generation blood flow diverting mesh stent Qiangyida PLUS.
Deepening cooperation
Why is it favored by giants?
With four separate agreements signed over three years, the collaboration between Johnson & Johnson and Changyida is progressing in depth.
Looking back on the collaboration, the partnership has achieved several significant milestones. In 2023, Johnson & Johnson partnered with Clindam for the first time to jointly develop the Clindam FlowGuard Mesh Stent , which was successfully launched in 2024. The product features a nickel-titanium alloy structure woven with four platinum-tungsten radiopaque wires, enabling excellent conformal adhesion and allowing for delivery to small diameter systems (0.017mm). It also boasts a closed-end design.
Building on the success of the first product, the second collaboration in January this year marked a significant leap forward. Led by Johnson & Johnson Medical's global R&D team in Neurointervention, the collaboration shifted from regional product development to collaborative innovation within a global R&D system. Subsequently, in September, the two parties expanded their cooperation to the field of microguidewires. The agreement signed during this China International Import Expo represents a further deepening and upgrade of the core product, PowerEasy PLUS.
At this year's China International Import Expo (CIIE), Qiangyida PLUS made its global debut. Utilizing a high-density mesh blood flow guiding principle, it effectively promotes intra-aneurysmal thrombus formation and achieves occlusion. Simultaneously, the Trichor next-generation femtosecond hysterosalpingography (DSH) microcatheter (global debut) and Qiangyhang's ChoyGlide microguidewire (global first launch) also made their appearance. These three products together constitute a domestically innovative solution for intracranial aneurysms.
So why does Johnson & Johnson repeatedly choose Clinic?
The answer lies in Changyida's strong underlying technological barriers. According to research, Changyida was founded in 2019 and currently has nine products on the market, among which the intracranial aneurysm-assisted embolization stent is an innovative medical device. Although Changyida's product portfolio primarily focuses on the neurointerventional field, its pipeline is gradually extending into neuromodulation.
What truly attracts industry giants is Changyida's dual capability of hand-weaving and high-end mechanical braiding. This capability is not only reflected in Changyida's products but also permeates the design of its innovative TaminoVIA® intracranial aneurysm-assisted embolization stent. This stent utilizes monofilament braiding to create a self-expanding elastic structure with closed ends, allowing for flexible adjustment of both the flare angle at the ends and the stent length. This process significantly enhances wall compliance, reduces vascular injury, and enables precise control of local metal coverage through length adjustment.
It is worth noting that in the manufacturing of flow-directing mesh stents, the weaving process is one of the core factors determining the metal coverage, mesh uniformity, and wall adhesion morphology. Therefore, as multinational giants accelerate localized innovation, local innovative medical device companies possessing key technological barriers have become indispensable innovation nodes in their global R&D landscape.
Track expansion
Accelerating industry reshuffling
Johnson & Johnson is continuously increasing its investment in the neurointerventional device market. Looking at the Chinese neurointerventional device market, against the backdrop of an aging population and rising incidence of cerebrovascular diseases, this sector is experiencing rapid expansion. According to Guoxin Securities, the Chinese neurointerventional device market size is projected to reach 12.8 billion yuan by 2025 , but currently, foreign brands still hold a significant share.
Focusing on the specific category of flow-directing mesh stents, clinical demand is continuously increasing, driven by both the growing number of patients with intracranial aneurysms and the rising penetration rate of interventional procedures. According to Frost & Sullivan data, the domestic market size for this segment has grown to 1.2 billion yuan by 2025.
However, it's worth noting that the gap between leading domestic companies and multinational giants is rapidly narrowing. According to data from Yaozhi Medical Devices, 16 Chinese companies have launched 24 flow-directing mesh stent products , representing 70.83% of the market share. More and more domestic medical device companies are also entering the top 10. However, objectively speaking, while the gap in market share and technological performance is continuously shrinking, domestic brands still face certain barriers in terms of accumulating long-term clinical evidence and building brand recognition among end-users.
Against this backdrop, centralized procurement has been the core driving force behind the increase in the domestic market share of blood flow guide mesh stents and even the entire neurointerventional product category in recent years, and it has also been a catalyst for accelerating industry reshuffling.
Blood flow diverting mesh stents have undergone multiple rounds of centralized procurement. According to data from Yaozhi Medical Devices, there are currently 83,143 procurement records for this type of consumable, with a total procurement amount of 225 million yuan.
However, a closer look at the procurement data reveals a clear discrepancy between volume and price. While the procurement volume of domestically produced products continues to rise, imported products still dominate in terms of bid value. Among them, Covidien leads in bid value, followed closely by MicroPort and Stryker. This indirectly confirms that foreign brands still hold a certain advantage in the high-end interventional field.
However, two more large-scale centralized procurements of consumables are expected to follow. The nationwide joint procurement of dense-mesh stents and infusion pumps, led by the Jiangsu Provincial Medical Insurance Bureau, has already begun intensive reporting work in many provinces across the country. Furthermore, the eighth batch of national centralized procurement of consumables may also target the neurointerventional field, potentially disrupting the future market landscape.
Conclusion
Against this backdrop, Johnson & Johnson's strategy of continuously increasing its localization efforts may be becoming increasingly clear. With centralized procurement becoming the norm, the market share of foreign giants is being continuously squeezed. Through its deep cooperation with Medtronic, Johnson & Johnson can not only absorb Medtronic's core local products with underlying technological barriers to complete its own product portfolio in specific scenarios, but also leverage the local team's keen insight into clinical pain points to achieve reverse innovation.

Source: https://news.yaozh.com/archive/49378.html